���景与受体作用机制 — 2026 Update

By Editorial Desk · published 2026-02-13 · last reviewed 2026-03-07 · Wiki

GHS-R1a raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.

背景与受体作用机制

现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin at a glance

Ipamorelin Background and Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Related pages on this site

• Comprehensive overview
• Comprehensive collection
• Tracked report
• Portable dataset
• Scheduled reference
• Reliable collection
• Connected notes
• Regional report

Ipamorelin Background and Pharmacology

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

Ipamorelin Background and Receptor Pharmacology

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

Analytical Characterization and Storage Practice

Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.

Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.

Notes from published material

SMD was used to investigate the stability of Alzheimer's protofibrils, to study the protein ligand interaction in cyclin-dependent kinase 5 and even to show the effect of electric field on thrombin (protein) and aptamer (nucleotide) complex among many other interesting studies.

In April 2010, the library announced plans to archive all public communication on Twitter, including all communication since Twitter's launch in March 2006. As of 2015, the Twitter archive remains unfinished. Before retiring in 2015, after 28 years of service, Billington had come "under pressure" as librarian of Congress. This followed a GAO report that described a "work environment lacking central oversight" and faulted Billington for "ignoring repeated calls to hire a chief information officer, as required by law." When Billington announced his plans to retire in 2015, commentator George Weigel described the Library of Congress as "one of the last refuges in Washington of serious bipartisanship and calm, considered conversation", and "one of the world's greatest cultural centers".

People taking rituximab had improved pain, function, reduced disease activity, and reduced joint damage based on X-ray images. After 6 months, 21% more people had improvement in their symptoms using rituximab and methotrexate. Biological agents should generally be used only if methotrexate and other conventional agents are not effective after a trial of three months. They are associated with a higher rate of serious infections as compared to other DMARDs. Biological DMARD agents used to treat rheumatoid arthritis include: tumor necrosis factor alpha inhibitors (TNF inhibitors) such as infliximab; interleukin 1 blockers such as anakinra, monoclonal antibodies against B cells such as rituximab, interleukin 6 blockers such as tocilizumab, and T cell co-stimulation blockers such as abatacept. They are often used in combination with either methotrexate or leflunomide. Biologic monotherapy or tofacitinib with methotrexate may improve ACR50, RA remission rates and function. Abatacept should not be used at the same time as other biologics. In those who are well controlled (low disease activity) on TNF inhibitors, decreasing the dose does not appear to affect overall function. Discontinuation of TNF inhibitors (as opposed to gradually lowering the dose) by people with low disease activity may lead to increased disease activity and may affect remission, damage that is visible on an x-ray, and a person's function. People should be screened for latent tuberculosis before starting any TNF inhibitor therapy to avoid reactivation of tuberculosis.

It has been shown in mice that in certain conditions neutrophils have a specific type of migration behaviour referred to as neutrophil swarming during which they migrate in a highly coordinated manner and accumulate and cluster to sites of inflammation.

Sources: en.wikipedia.org

Further detail

== Causes == Mutations in the COL2A1 gene can cause a number of skeletal abnormalities, including achondrogenesis type 2. Instructions for producing a protein that produces type II collagen are provided by this gene. Type II collagen molecule assembly is disrupted by mutations in the COL2A1 gene, impairing the normal development of bones and other connective tissues. Because achromogenesis type 2 is caused by a mutated gene that only needs one copy in each cell, it is regarded as an autosomal dominant disorder.

On 17 February, an Israeli drone strike hit a car in Sidon, killing Mohammed Shaheen, Hamas's operations chief in Lebanon. On the ceasefire's deadline on 18 February, the IDF withdrew from all of southern Lebanon, apart from five hilltops on the border—namely al-Aziyah, al-Awaida, el-Hamames, Jabal Bilat, and Labbouneh. On 22 March, six rockets were fired at Metula from southern Lebanon, with three crashing in Lebanon and the rest being intercepted. Hezbollah denied responsibility for the attack. The IDF responded with strikes on dozens of Hezbollah targets across southern Lebanon, including rocket launchers. On 25 March, an Israeli drone strike on a vehicle in Qaaqaait al-Jisr killed Hassan Kamal Halawi, who commanded Hezbollah's anti-tank missile unit in southern Lebanon. On 28 March, two rockets were fired at Kiryat Shmona, with one falling short in Lebanon and the other being intercepted. In response, the IDF said that it struck several Hezbollah targets in southern Lebanon, including command centers. A strike in Kfar Tebnit killed three people and injured 18 others. An airstrike also hit a building in Dahieh that the IDF accused of storing drones from Hezbollah's Unit 127, in the first attack in Beirut since the ceasefire went into effect. On 1 April, an Israeli airstrike on an apartment in Dahieh killed four people and injured seven others. Among the dead were senior Hezbollah official Hassan Bdeir, who the IDF accused of planning to attack Israeli civilians alongside Hamas, and his son, who was a Hezbollah member.

==== Above-ground disposal ==== Dry cask storage typically involves taking waste from a spent fuel pool and sealing it (along with an inert gas) in a steel cylinder, which is placed in a concrete cylinder which acts as a radiation shield. It is a relatively inexpensive method which can be done at a central facility or adjacent to the source reactor. The waste can be easily retrieved for reprocessing.

Sources: en.wikipedia.org

Supporting material

== Efficacy == There is currently no standardized form of dry needling. There is a general scarcity of extensive research in the field. Many studies published about dry needling are not randomized, contain small sample sizes, and have high dropout rates. A review recommended the usage of dry needling, compared to sham or placebo, for decreasing pain immediately after treatment and at 4 weeks in patients with upper quarter myofascial pain syndrome. However, the authors caution that "the limited number of studies performed to date, combined with methodological flaws in many of the studies, prompts caution in interpreting the results of the meta-analysis performed". Similarly, a second review of dry needling found insufficient high-quality evidence for the use of direct dry needling for short and long-term pain and disability reduction in patients with musculoskeletal pain syndromes. The same review reported that robust evidence validating the clinical diagnostic criteria for trigger point identification or diagnosis is lacking and that high-quality studies demonstrate that manual examination for the identification and localization of a trigger point is neither valid nor reliable between examiners.

=== 2024 discontinuation === In September 2024, the forums were discontinued by Bodybuilding.com, and its webpages redirected to a company statement which mentioned: "No good growth came without change. We're building new ways to connect our global community". This was highly controversial among the site's long-time visitors. Many of its users migrated to successor forums, mainly Newmisc.com. As of May 2026, the forums are to be on track to return; when users visit the forums section of the website they're prompted with a splash screen stating such.

=== Pharmacodynamics === Butane-1,4-diol seems to have two types of pharmacological actions. The major psychoactive effects of 1,4-butanediol are because it is metabolized into GHB; however, there is a study suggesting that 1,4-butanediol may have potential alcohol-like pharmacological effects on its own. The study arrived at this conclusion based on the finding that butane-1,4-diol coadministered with ethanol led to potentiation of some of the behavioral effects of ethanol. However, potentiation of ethanol's effects may simply be caused by competition for the alcohol dehydrogenase and aldehyde dehydrogenase enzymes with co-administered 1,4-butanediol. The shared metabolic rate-limiting steps thus leads to slowed metabolism and clearance for both compounds including ethanol's known toxic metabolite acetaldehyde. Another study found no effect following intracerebroventricular injection of butane-1,4-diol in rats. This contradicts the hypothesis of butane-1,4-diol having inherent alcohol-like pharmacological effects. Like gamma-hydroxybutyric acid, butane-1,4-diol is safe only in small amounts. Adverse effects in higher doses include nausea, vomiting, dizziness, sedation, vertigo, and potentially death if ingested in large amounts. Anxiolytic effects are diminished and side effects increased when used in combination with alcohol.

In immunology, the mononuclear phagocyte system or mononuclear phagocytic system (MPS), also known as the macrophage system, is a part of the immune system that consists of the phagocytic cells located in reticular connective tissue. The cells are primarily monocytes and macrophages, and they accumulate in lymph nodes and the spleen. The Kupffer cells of the liver and tissue histiocytes are also part of the MPS. The mononuclear phagocyte system and the monocyte macrophage system refer to two different entities, often mistakenly understood as one. "Reticuloendothelial system" is an older term for the mononuclear phagocyte system, but it is used less commonly now, as it is understood that most endothelial cells are not macrophages. The mononuclear phagocyte system is also a somewhat dated concept trying to combine a broad range of cells, and should be used with caution.

Sources: en.wikipedia.org

Frequently asked questions